The Altria story

What drives the business

• Altria's long-term transition pairs its Marlboro cigarette franchise with Copenhagen and Skoal smokeless tobacco, on! nicotine pouches and NJOY e-vapor products, although illicit e-vapor competition has prompted it to reassess its smoke-free goals.
• Smokeable products accounted for 88% of revenue in the quarter to June 2026, and Marlboro held 59.6% of the premium cigarette segment.
• Higher cigarette pricing and refunds of taxes and duties on imports helped lift the smokeable products adjusted operating company income margin to 64.8% in the quarter to June 2026, despite lower volume, greater promotional spending and a shift toward discount brands.
• Nicotine pouches reached 59.9% of the oral tobacco category in the quarter to June 2026, making Helix's on! PLUS expansion central to competing as consumers move away from traditional smokeless tobacco.
• Altria expects its Optimize & Accelerate initiative to deliver cumulative savings of at least $600 million by the end of 2029, with those savings reinvested in its businesses.

What the price assumes

At $69.13 per share, the reverse DCF implies free cash flow after stock pay grows 1.5% a year for ten years, using a 10.2% discount rate.

That compares with delivered growth of 6.4% a year over the last 10 years and the TenQ check's 5.2% bar, which slows the historical record halfway toward 4%.

The implied growth passes that check, but the 7.9% free cash flow yield is below its historical 13.0%, and the earnings valuation also fails the comparison with Altria's own history.

Value MO on your own assumptions

What could change the story

• Cigarette pricing faces pressure from consumers shifting toward discount brands, whose industry retail share reached 33.8% in the quarter to June 2026, while revenue growth over the last twelve months was -0.6%.
• The smoke-free transition has not prevented oral tobacco revenue from falling 5.3% in the quarter to June 2026, and on! held 14.4% of the nicotine pouch category, down 1.7 share points from the prior year.
• Altria's 2026 guidance assumes NJOY ACE remains absent from the marketplace, while slower enforcement against illicit e-vapor products leaves the business exposed to further impairments.
• Tobacco and health and certain other litigation items and related interest costs produced $95 million in pretax charges in the quarter to June 2026, illustrating a continuing claim on cigarette earnings.
• Total debt of $24.6 billion against $2.4 billion in cash and short-term investments, negative equity and a failed near-term liquidity check limit financial flexibility, even as free cash flow covers shareholder distributions.

What to watch next

• Altria's narrowed 2026 adjusted diluted EPS guidance is $5.61 to $5.72, representing growth of 3.5% to 5.5%, following 4.9% growth in the first half of 2026.
• The planned national expansion of 12-milligram on! PLUS in the third quarter of 2026 and additional flavors in the fourth quarter of 2026 make pouch market share, oral tobacco shipment volume and promotional spending key measures of progress.
• Altria expects a greater benefit from cigarette import and export activity in the second half of 2026 than in the first half, making those contributions important alongside pricing and domestic shipment declines.
• Capital expenditure guidance rose to $375 million to $450 million for 2026, primarily for USSTC manufacturing consolidation, putting cash generation and consolidation costs alongside earnings growth in the next releases.

Sources

• Altria's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The MO stock report, for every figure and check